BG Medicine Receives Notice of Non-compliance from Nasdaq | GenomeWeb

NEW YORK(GenomeWeb) – BG Medicine said after the close of the market on Friday that it has received a notice of non-compliance from Nasdaq indicating that the company's stock is subject to delisting unless it makes a timely request for a hearing before the Nasdaq Listing Qualifications Panel. 

BG Medicine said that it will request a hearing at which it will present its plan to regain and maintain compliance with the applicable listing requirements. The company's stock will continue to trade on Nasdaq pending the hearing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.